Combine the Power of PROPHET *NSCLC*™ with PD-L1 to Help Paint the Full Patient Picture

PROPHET® is a blood-based test that helps predict the Clinical Benefit of first-line Immune Checkpoint Inhibitor (ICI) therapy.

The PD-L1 Tissue Challenge

PD-L1 ≥50%	PD-L1 1–49%	PD-L1 <1%



PD-L1 tissue testing is a critical tool for making ICI treatment decisions, but has limitations

- Tumor heterogeneity - PD-L1 expression varies substantially in different locations throughout the same tumor[1]
- Significant differences in PD-L1 expression are often found between primary tumors and their metastatic sites[2]
- Single tissue biopsies may not accurately represent overall tumor PD-L1 expression[3,4]
- PD-L1 does not measure the host immune response or systemic biology beyond the tumor, including metastatic disease



PROPHET *NSCLC*™

The Single Blood Draw Answer

388 Proteins. Multiple Dimensions.

In Depth Tumor Biology and Host Response Analysis.[5]

PROPHET® lens

Proteomic blood profile adds critical dimensions to guide ICI treatment decisions

Tumor Microenvironment

- Tumor Cells
- Immune Cells
- Extracellular Matrix
- Angiogenesis & Vasculature

What PROPHET® Reveals From One Blood Draw

- Tumor + Host immune response
- Comprehensive, actionable systemic insights
- Provides additional information to help predict ICI clinical benefit and support first-line treatment decisions.[6]

References

1. McLaughlin J et al. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer. JAMA Oncology, 2016; 2:46–54
2. Mansfield AS, et al. Temporal and Spatial Discordance of PD-L1 Expression and Lymphocyte Tumor Infiltration Between Paired Primary Lesions and Brain Metastases. Annals of Oncology, 2016.
3. Ilie M et al. Comparative Study of PD-L1 Status Between Surgically Resected Specimens and Matched Biopsies of NSCLC Patients Reveals Major Discordances. Annals of Oncology, 2016.
4. Wang L, et al. PD-L1 Expression in NSCLC: Heterogeneity by Pathologic Types, Tissue Sampling and Metastasis. Journal of Thoracic Disease, 2021.
5. Harel M, et al. Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications. JITC, 2025.
6. Christopoulos, P, et al. Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer. JCO PO, 2024.

ONCOHOST
GUIDED ONCOLOGY

ONCOHOST GUIDED ONCOLOGY

Your Insights. Amplified. By PROPHET™

Optimizing immunotherapy outcomes for mNSCLC patients with a single blood draw

ABOUT THE TEST

How PROPHET *NSCLC*™ Works

1 Blood Collection
PROPHET® requires only a single blood draw using a 10 mL Streck tube. No tumor biopsy or fresh tissue required. Order Simultaneously with NGS & PD-L1.

2 Proteomics Profiling
Sample processed at our CLIA-registered, CAP-accredited lab. A panel of 388 resistance-associated proteins (RAPs) is quantified.

3 AI Analysis
Identifying proteomic expression patterns reflecting immune regulation, inflammation, metabolic pathways, and tumor-host interactions.

4 Personalized Report
The PROPHET® score is a continuous variable ranging from 0-10 where a NEGATIVE (0-4.9) or POSITIVE (5.0-10) result correlates with the probability of Clinical Benefit (CB) from PD-1/PD-L1 inhibitor therapy. The higher the score, the greater the likelihood of CB.

CLINICAL UTILITY

PROPHET *NSCLC*™ - Guiding Within the Guidelines

PROPHET*NSCLC*® does not change guidelines — it helps you navigate them more precisely.
Used alongside PD-L1, it helps identify the optimal first-line therapy for each individual patient.

POSITIVE

Patient's PROPHET® Result: POSITIVE | Score 7.6/10



The PROPHET® score is a continuous variable from 0 to 10 that correlates with the predicted probability of clinical benefit (CB) from PD-1/PD-L1 inhibitors. The higher the score, the greater the likelihood of CB. CB is defined as Progression Free Survival (PFS) greater than 12 months.

PROPHET® POSITIVE Treatment Recommendations by PD-L1 Status

There is a higher predicted clinical benefit from PD-1/PD-L1 inhibitors for PROPHET® POSITIVE result.[1]
For patients with:
- **PD-L1 status ≥50%, consider first-line ICI monotherapy.**
- **PD-L1 status 1-49% and <1%, there is predicted clinical benefit from first-line ICI + chemotherapy.**

Refer to NCCN Guidelines® NSCLC for list of Preferred first-line treatment options.[2]
Treatment selection should incorporate the patient's PROPHET® score, PD-L1 status, additional clinicopathologic and molecular factors, and physician's clinical judgement.
**OncoHost does not perform PD-L1 testing. PD-L1 results reflect institutional pathology reporting and should be used alongside the PROPHET® result.*

PD-L1 Status	<1%	1-49%	≥50%
PROPHET® Direction	Consider ICI + Chemotherapy	Consider ICI + Chemotherapy	Consider ICI Monotherapy
Overall Survival by PD-L1 Status			

HR – Hazard Ratio | CI - Confidence Interval (95%) | OS – Overall Survival | ICI – Immune Checkpoint Inhibitor

NEGATIVE

Patient's PROPHET® Result: NEGATIVE | Score 3.6/10



The PROPHET® score is a continuous variable from 0 to 10 that correlates with the predicted probability of clinical benefit (CB) from PD-1/PD-L1 inhibitors. The higher the score, the greater the likelihood of CB. CB is defined as Progression Free Survival (PFS) greater than 12 months.

PROPHET® NEGATIVE Treatment Recommendations by PD-L1 Status

There is a lower predicted clinical benefit from PD-1/PD-L1 inhibitors with a PROPHET® NEGATIVE result.[1]
For patients with:
- **PD-L1 status ≥50%, consider first-line ICI + chemotherapy.**
- **PD-L1 status of 1-49%, consider Dual ICI ± chemotherapy or ICI + chemotherapy.**
- **PD-L1 status of <1%, consider Dual ICI ± chemotherapy.**

Refer to NCCN Guidelines® NSCLC for list of Preferred and Other first-line treatment options.[2]
Treatment selection should incorporate the patient's PROPHET® score, PD-L1 status, additional clinicopathologic and molecular factors, and physician's clinical judgement.
**OncoHost does not perform PD-L1 testing. PD-L1 results reflect institutional pathology reporting and should be used alongside the PROPHET® result.*

PD-L1 Status	<1%	1-49%	≥50%
PROPHET® Direction	Consider Dual ICI ± Chemotherapy	Consider Dual ICI ± Chemotherapy **or** ICI + Chemotherapy	Consider ICI + Chemotherapy
Overall Survival by PD-L1 Status			

HR – Hazard Ratio | CI - Confidence Interval (95%) | OS – Overall Survival | ICI – Immune Checkpoint Inhibitor

PROPHET® Sees Beyond the Surface With Precision Proteomics

More Insights | More Confidence | Better Decisions | Better Outcomes

OncoHost Inc. | 1110 SE Cary Parkway | Suite 205 l Cary, NC 27518
oncohost.com | Client Services: 1-855-950-2112 l Fax: 1-919-415-1308 | Email: contact@oncohost.com